zofenopril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
angiotensin-converting enzyme inhibitors 2866 81872-10-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zofenopril
  • zofenopril calcium
  • SQ-26991
  • SQ. 26,991
  • zofenopril potassium
  • Molecular weight: 429.55
  • Formula: C22H23NO4S2
  • CLOGP: 4.02
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 74.68
  • ALOGS: -5.14
  • ROTB: 8

Drug dosage:

DoseUnitRoute
30 mg O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 65 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PRKDC,STK33,SYK,TEK,TTK,ZAP70 40
kinase-selectivity-class ACVR2B,AXL,BRAF,EPHB4,ERBB2,GRK2,MAP2K6,STK33,TEK 9
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 116.88 39.78 65 1351 276388 90350643
Vascular stent thrombosis 100.12 39.78 17 1399 1099 90625932
Bradycardia 95.16 39.78 39 1377 83808 90543223
Hyponatraemic syndrome 67.28 39.78 11 1405 563 90626468
Syncope 52.52 39.78 30 1386 132633 90494398
Herbal interaction 48.37 39.78 7 1409 158 90626873
Hallucination, gustatory 45.42 39.78 6 1410 67 90626964
Hyperhidrosis 43.93 39.78 27 1389 136278 90490753
Psychogenic visual disorder 43.41 39.78 5 1411 15 90627016
Muscle contracture 42.87 39.78 9 1407 1812 90625219

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 112.53 38.45 74 997 266925 42353339
Enzyme inhibition 57.95 38.45 8 1063 76 42620188
Initial insomnia 45.47 38.45 12 1059 4018 42616246
Blood glucose fluctuation 43.93 38.45 12 1059 4575 42615689

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 213.75 31.68 136 2423 500047 110086693
Bradycardia 90.94 31.68 52 2507 155465 110431275
Vascular stent thrombosis 71.11 31.68 17 2542 4144 110582596
Hyponatraemic syndrome 65.78 31.68 12 2547 785 110585955
Ventricular arrhythmia 60.51 31.68 18 2541 10069 110576671
Enzyme inhibition 53.80 31.68 8 2551 145 110586595
Hypertensive crisis 48.46 31.68 19 2540 24353 110562387
Hallucination, gustatory 42.98 31.68 6 2553 68 110586672
Syncope 40.24 31.68 35 2524 202501 110384239
Blood glucose fluctuation 38.73 31.68 12 2547 7686 110579054
Psychogenic visual disorder 38.24 31.68 5 2554 33 110586707
Pulmonary interstitial emphysema syndrome 36.88 31.68 7 2552 568 110586172
Hallucination, olfactory 36.65 31.68 7 2552 587 110586153
Herbal interaction 36.29 31.68 7 2552 619 110586121
Muscle contracture 35.46 31.68 9 2550 2799 110583941
Initial insomnia 35.19 31.68 12 2547 10377 110576363
Apraxia 33.39 31.68 9 2550 3531 110583209
Inferior vena cava dilatation 33.25 31.68 7 2552 960 110585780

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C09AA15 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, PLAIN
ACE inhibitors, plain
ATC C09BA15 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and diuretics
ATC C09BB14 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors and calcium channel blockers
ATC C09BX07 CARDIOVASCULAR SYSTEM
AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
ACE INHIBITORS, COMBINATIONS
ACE inhibitors, other combinations
MeSH PA D000806 Angiotensin-Converting Enzyme Inhibitors
MeSH PA D000959 Antihypertensive Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011480 Protease Inhibitors
CHEBI has role CHEBI:35457 EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:35623 anticonvulsant
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:68494 apoptosis inhibitor
CHEBI has role CHEBI:77307 cardioprotective agent
CHEBI has role CHEBI:49103 drug metabolite

Related Drugs by ATC class:

C09AA ACE inhibitors, plain 15 drugs
benazeprilcaptoprilcilazaprildelaprilenalaprilfosinoprilimidaprillisinoprilmoexiprilperindoprilquinaprilramipril show all 15 →
C09BA ACE inhibitors and diuretics 11 drugs
benazeprilcaptoprilcilazaprildelaprilenalaprilfosinoprillisinoprilmoexiprilperindoprilquinaprilramipril
C09BB ACE inhibitors and calcium channel blockers 13 drugs
amlodipinebenazeprildelaprilenalaprilfelodipinelercanidipinelisinoprilmanidipinenitrendipineperindoprilramipriltrandolapril show all 13 →
C09BX ACE inhibitors, other combinations 7 drugs
amlodipinebisoprololhydrochlorothiazideindapamidenebivololperindoprilramipril

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypertensive disorder indication 38341003 DOID:10763




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.94 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Angiotensin-converting enzyme Enzyme INHIBITOR IC50 9.40 CHEMBL SCIENTIFIC LITERATURE
Angiotensin-converting enzyme Enzyme Ki 9.40 CHEMBL
Angiotensin-converting enzyme Enzyme IC50 8.10 CHEMBL

External reference:

IDSource
D03767 KEGG_DRUG
C0078836 UMLSCUI
CHEBI:78539 CHEBI
ZED PDB_CHEM_ID
CHEMBL331378 ChEMBL_ID
CHEMBL2105776 ChEMBL_ID
DB13166 DRUGBANK_ID
C044958 MESH_SUPPLEMENTAL_RECORD_UI
92400 PUBCHEM_CID
6462 IUPHAR_LIGAND_ID
5535 INN_ID
81938-43-4 SECONDARY_CAS_RN
290ZY759PI UNII
DB08766 DRUGBANK_ID
259493 RXNORM
008183 NDDF
008184 NDDF
703340007 SNOMEDCT_US
703341006 SNOMEDCT_US
703342004 SNOMEDCT_US
703662000 SNOMEDCT_US
703663005 SNOMEDCT_US
C0085065 UMLSCUI
CHEMBL16332 ChEMBL_ID
75176-37-3 SECONDARY_CAS_RN
3034048 PUBCHEM_CID
6463 IUPHAR_LIGAND_ID
6599 INN_ID
4G4WDK2YBS UNII
CHEBI:82602 CHEBI
290ZY759PI INXIGHT DRUGS
4G4WDK2YBS INXIGHT DRUGS

Pharmaceutical products:

None